+

WO1993006846A1 - Parathyroid hormone analogues and use in osteoporosis treatment - Google Patents

Parathyroid hormone analogues and use in osteoporosis treatment Download PDF

Info

Publication number
WO1993006846A1
WO1993006846A1 PCT/US1992/008478 US9208478W WO9306846A1 WO 1993006846 A1 WO1993006846 A1 WO 1993006846A1 US 9208478 W US9208478 W US 9208478W WO 9306846 A1 WO9306846 A1 WO 9306846A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
parathyroid hormone
structure shown
hormone analogue
leu
Prior art date
Application number
PCT/US1992/008478
Other languages
French (fr)
Inventor
Peter K. T. Pang
Jie Shan
Original Assignee
Pang Peter K T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pang Peter K T filed Critical Pang Peter K T
Publication of WO1993006846A1 publication Critical patent/WO1993006846A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • PTH Parathyroid hormone
  • PTH is a polypeptide and the amino acid seguences of bovine and human PTH are closely related. Only the residues at locations one, seven and sixteen differ between the two. Synthetic polypeptides containing the first thirty-
  • PTII 20 four residues of PTII may be prepared using the method disclosed by Erickson and Merrifield, The Proteins. Neurath et al. , Eds. , Academic Tress, New York, 197G, page 257, preferably as modified by the method of Hodges et al., Peptide Research, 1, 19 (1988).
  • the antagonist of PTH is calcitonin, which acts to reduce
  • Intracellular calcium has been shown to affect changes in vascular tension, as can be measured by changes in blood pressure.
  • U.S. Patent Application 603,745 describes one method which has been discovered to regulate calcium uptake in vascular cells.
  • Osteoporosis is a progressive disease which is particularly characteristic of post enopausal women, and results in the reduction of total bone mass. The sequelae frequently involve fractures of load-bearing bones and the physical degenerations characteristic of immobilizing injuries. Osteoporosis is associated with hyperthyroidi ⁇ m, hyp ⁇ rparathyroidism, Cushings syndrome and the use of certain steroidal drugs. Remedies historically have involved increase in dietary calcium, estrogen therapy and increased doses of vitamin D.
  • PTH has been used to treat osteoporosis.
  • PTII may exhibit oth ⁇ r undesired pharmalogical effects, sucli as hypotension and smooth muscle relaxation (e.g. relaxation of gastrointestinal organs, utorus?, tracheal and vas deferens) ⁇ s well ar, posi ivo chronotropic and inotropic effects on the heart.
  • smooth muscle relaxation e.g. relaxation of gastrointestinal organs, utorus?, tracheal and vas deferens
  • the relaxation effects of PTH on smooth muscle as well as positive chronotropic and inotropic effects of PTH are described in Pang et al, Trends in Pharmacological Sciences. Vol. 7, No. 9, pp. 340-341 (September 198G) .
  • U.S. Patent No. 4,771,124 discloses the property of bovine and human PTH analogues wherein Trp is substituted by amino acids phenylalanine, leucine, norleucine, valine, tyrosine, beta-naphtylalanine and alpha-naphtylalanine as a PTH antagonist. While it was suggested that these analogues might be useful in the treatment of osteoporosis, it was based on the analogues antagonistic action to PTII. Furthermore, there was no data to indicate the effectiveness these analogues on bone or other tissue.
  • analogues with substituted at Trp 23 with leucine, phenylalanine or tyrosine would produce undesired secondary effects of smooth muscle relaxation, vascular smooth muscle calcium change as well as positive t ⁇ chronotropic and inotropic effects on the heart.
  • Fig. lb shows the structure of natural human PTH (SEQ ID NO:2) .
  • Fig. 2a shows the structure of bPTH (1-34) with position 23 substituted with Xaa (SEQ ID NO:3).
  • Figs. 2b-2p show the structure of bPTH (1-34) with position 23 substituted with Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, Ile, Lys, Met, Pro, Ser or Thr, respectively (SEQ ID NO:4 - SEQ ID NO:18) .
  • Fig. 3a shows the structure of hPTH (1-34) with position
  • Fig. 5 shows the structure of hPTH with position 23 substituted with Xaa (SEQ ID NO:36).
  • Fig. 6 shows the effect of bPTH-(l-34) and its analogues on diastolic blood pressure of anestlietized Sprague-Dawley rats. Csll4 had no effect.
  • Fig. 7 shows the effect of bPTH-(l-34) and its analogues on systolic blood pressure of anesthetized Sprague-Dawley rats. Csll4 had no effect.
  • Fig. 8 shows the vasorelaxing effect of bPTH-(l-34) and its analogues on rat tail artery helical strip in vitro. Csll4 had no effect.
  • Figs. 11 a-c show the depolarizing concentrations of KCl increasing calcium ion levels in cultured osteoblasts. Csll4 inhibits the KCl effect.
  • Fig. 12 shows the relation between the relaxation curves of Sprague-Dawley rat tail artery helical strips, precontracted with AVP when treated with Csll4, Csll7 and Cs201.
  • Fig. 13 shows the effects illustrated in. Fig. 12, using
  • Fig. 16 shows the effect of Csll4 on the intracellular calcium concentration in the presence of KCl in UMR cells in culture.
  • Fig. 17 shows a comparison of the effect of Cs205 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
  • Fig. 18 shows the dose-response relationship between Cs205 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
  • Fig. 19 shows a comparison of the effect of Cs201 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
  • Fig. 20 shows the dose-response relationship between Cs201 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
  • Fig. 21 shows a comparison of the effect of Cs503 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
  • Fig. 25 shows a comparison of the effect of Cs501 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
  • Fig. 28 shows the dose-response relationship between Cs207 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
  • Fig. 29 shows the effect of Cs207 on intracellular calcium increase stimulated by KCl in cultured UMR osteoblast cells.
  • Fig. 40 shows the effect of Csll4 (B) on intracellular calcium concentration stimulated by KCl in cultured UMR cells at 30 mM KCl.
  • Fig. 41 shows the effect of Cs88 [bPTH-(l-34) ] on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.
  • Fig. 44 shows the effect of Cs88 on intracellular calcium concentration stimulated by KCl in cultured UMR cells.
  • Fig. 46 shows the effect of Cs501 on the intracellular calcium concentration stimulated by KCl in the presence of KCl in UMR cells in culture.
  • Fig. 47 shows the effect of CslOOl on the intracellular calcium concentration stimulated by KCl in the presence of KCl in UMR cells in culture.
  • Fig. 48 shows the effect of Csll4 on the contractility and contraction rate of right atriai tissue of Sprague-Dawley rats.
  • Fig. 49 shows the effect of Cs201 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 50 shows the effect of Cs205 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 51 shows the effect of Cs206 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 52 shows the effect of Cs207 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 53 shows the effect of Cs208 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 50 shows the effect of Cs205 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 51 shows the effect of Cs206 on the contractility and contraction rate of right atrial tissue of Sprague-Daw
  • Fig. 54 shows the effect of Cs209 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 55 shows the effect of Cs211 on the contractility and contrnction rate of right atrial. tissue of Sprague-Dawley rats.
  • Fig. 56 shows the effect of Cs212 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 57 shows the effect of Cs213 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 58 shows the effect of Cs214 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 59 shows the effect of Cs215 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 60 shows the effect of Cs220 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 61 shows the effect of Cs501 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 62 shows the effect of Cs503 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley ratr,
  • Fig. 63 shows the effect of Cs2001 and CslOOl on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 64 shows the effect of Cs219 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 65 shows the effect of Cs218 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • Fig. 66 shows the effect of Cs502 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
  • PTH PTH
  • Ca2+ calcium uptake from the gastrointestinal tract and the deposition and removal of calcium from bone.
  • Calcium also has been found to be effective in the maintenance of blood pressure.
  • Control of calcium in the walls of blood vessels is a useful therapeutic regimen for controlling hypertension and calcium channel blockers, which prevent the introduction of calcium into cell walls, is a conventional therapy for hypertension. Needleman et al. in Goodman and Gil an's The Pharmacological Basis of Therapeutics. MacMillan, New York, (1985), page 816 ff.
  • Therapeutic dosages of PTH will, in some individuals, result in unacceptable diminution of blood pressure and may result in relaxation of smooth muscles such as gastrointestinal, uterus, tracheal, vas deferens as well as exhibit positive chronotropic and inotropic effects on the heart.
  • smooth muscle relaxation effects and positive chronotropic and inotropic effects on the heart it was envisaged that the structure of PTH could be modified to decouple the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic function from the bond calcium and bone deposition function.
  • Trp tryptophane
  • the * procedure of Erickson and Merrifield, as modified by Hodges et al.. as described above, may be used to synthesize synthetic PTH or fragments thereof.
  • the procedure enables substitution for the naturally occurring PTH at substantially every location and it is possible to prepare both bovine and human synthetic PTH at full length or in the sequence of the first thirty-four amino acids, which is .more facilely performed. Such substitution can also be accomplished by genetic engineering.
  • Substitution at position twenty-three invariably alters the observed hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects, whether the full length PTH or the 1-34 fragment is administered.
  • Substitution of Ala for Trp at position twenty-three is particularly preferred because the change in blood pressure, smooth muscle relaxation and positive chronotropic and inotropic effects from this substitution are minimal and calcium uptake, as measured in osteoblasts, mimics the results from the administration of native PTH.
  • the 1-34 PTH fragment with Ala 23 or other amino acids is particularly preferred because the pharmacological properties are those which are desired and the difficulty of synthesis is minimized. Synthesis of the compounds used in the development of this invention was performed at Alberta Peptide Institute (API) and the cooperation of API is gratefully acknowledged.
  • bovine parathyroid hormone bPTH
  • human parathyroid hormone hPTH
  • Representative synthetic analogues are described in Table 1 and are further shown in Figs. 2-5 and SEQ ID N0:3-SEQ ID NO:36.
  • the hypotensive effects of these analogues is shown in Figs. 6, 7, 17, 19, 21, 23, 25, 27, 31, 35, 36, and 41. All of the analogues produce either no or less diminution of blood pressure than does native PTH.
  • the Ala 23 analogue provides almost no change in blood pressure, either systolic or diastolic, over a range of 0-5 ⁇ g/kg. At the level of 5 ⁇ g/kg of PTH, the blood pressure in Sprague-Dawley rats is such that they are essentially moribund.
  • the strips may be precontracted using other pressor substances such as norepinephrine (NE) or KCl.
  • NE norepinephrine
  • KCl KCl
  • osteoporosis is a progressive syndrome, a model is required and the use of cultured osteoblasts of the UMR-106 rat osteosarcoma cells, ATCC CRL 1661 have been used as the model.
  • Intracellular calcium concentration change in these cells has been monitored using the FURA-2 method, wherein a fluorescent dye which is specific for calcium is used as a marker for calcium uptake into the cells.
  • Cells are incubated with 1-10 ⁇ M of the acetomethoxy ester of FURA-2 for 30-60 minutes. Upon uptake, the ester is hydrolyzed to release free FUR ⁇ -2, which selectively binds free Ca + .
  • FUR ⁇ -2 has a characteristic fluorescence spectrum, which wavelength is shifted when the dye binds to free Ca 2+ .
  • Ca 2+ which is present in the cell can be quantified by exciting the dye at two different wavelengths, 340 and 380 nm.
  • the emission fluorescence is measured at 510 nm.
  • the calcium concentration is proportional to the ratio of the fluorescent emission when excited at 340 nm to the emission at 380 nm. It is conventional to report the concentration of calcium within the cell in terms of the fluorescence ratio, the 340/380 ratio. This technique is described in Grynkiewicz et al. , J. Biol. Chem. , 260, 3440 (1985) and Pang et al., P. N. A. S. (USA) , 87, 623 (1990) .
  • Figs. 9, 10 a-d, 11 a-c, 16, 29, 30, 33, 34, 38, 39, 40, 43, 44 and 45-47 illustrate the results of the above-described measurements when inhibitors such as an anti-osteoporotic agent (788) or bPTH-(l-34) or Csll4 were used in the presence of KCl.
  • inhibitors such as an anti-osteoporotic agent (788) or bPTH-(l-34) or Csll4 were used in the presence of KCl.
  • the PTH analogues whether full length or 1-34, which contain anomalous amino acids at position twenty-three (most particularly those which contain Ala 23 ) do not effect a hypotensive and smooth muscle relaxation response, including positive chronotropic effects, but do inhibit calcium uptake as stimulated by KCl in osteoblasts, which indicates that these compounds would have the same effect on bone cells as PTH and would be useful in the treatment of osteoporosis in mammals and, particularly, in man, without the aformentioned deleterious side effects in the elderly-
  • Trp 23 is substituted by other amino acids in 1-84 PTH and in the 1-34 analogues.
  • the effect on KCl induced in osteoblasts is essentially unchanged for 1-84 or 1-34 PTH.
  • the effect on bone cells is unchanged from PTH.
  • the physiological significance of an inhibiting effect on the KCL induced calcium uptake in bone cells is not yet understood.
  • the analogues interact fully with bone cell receptor activity. The fact that the same effect is seen for both PTH and the analogues disclosed herein suggests that the site of interaction with the osteoblast cell receptor is unchanged by the substitution.
  • the analogues of trie present invention can be used in the 5 treatment of osteoporosis and other bone related diseases and disorders involving bone cell calcium regulation.
  • the analogues of the present invention may be administered to a warm-blooded mammalian in need thereof, particularly a human, by parental, topical, rectal administration or by
  • the analogues may be conventionally formulated in a parenteral dosage form compounding about 1 to about 300 mg per unit of dosage with a conventional vehicle, excipient, binder, preservative, stabilizer, color, agent or the like as called for by accepted pharmaceutical practice.
  • a 1 to 10 ml intravenous, intramuscular or subcutaneous injection would be given one to four times daily.
  • the injection would contain an analogue of the present invention in an aqueous isotonic sterile solution or suspension optionally with a preservative such as phenol or 0 a solubilizing agent such as ethylenediaminetetraacetic acid (EDT ⁇ ) .
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. 5 Synthetic monoglycerides, diglycerides, fatty acids (such as oleic acid) find use as fixed oil in the preparation of in ectables.
  • the analogues of the present invention can be prepared in the form of suppositories by 0 mixing with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols.
  • the analogues of the present invention can be prepared in the form of ointments, jellies, solutions, suspensions or dermal adhesive patches. 5
  • analogues of the present invention may be administered by a spinhaler turbo-inhaler device obtained from Fisons Corporation of Bedford, Massachusetts, at a rate of about 0.1 to 50 mg per capsule, 1 to 8 capsules being administered daily for an average human.
  • the compounds of the present invention are administered at the rate of about 100 to 1000 micrograms per "puff" or activated release of a standard volume of propellant.
  • the liquid aerosol would be given at the rate of 1 to 8 "puffs" per day with variation in dosages due to the severity of the conditions being treated, the weight of the patient and the particle size distribution of the aerosol.
  • a fluorinated hydrocarbon or isobutane find use as propellants for liquid aerosols.
  • Daily doses are in the range of about 0.01 to about 200 mg per kg of body weight, depending on the activity of the specific compound, the age, weight, sex and conditions of the subject to be treated, the type and severity of the disease, the frequency and route of administration.
  • the amount of active ingredient that may be combined with the carried materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.
  • the following examples demonstrate the utility of applicants' invention. The examples are not limiting, but are illustrative only, and modifications which would be apparent to those skilled in the art are included within the scope of this disclosure.
  • Sprague-Dawley (S-D) rats were anaesthetized with pentobarbital and a cannula was inserted into the carotid artery. The rats were kept sedated during the procedure and were injected with PTH peptides only when the blood pressure of the rats were stable. Peptides were injected through a cannula in the jugular vein, in amounts of 1, 3 and 5 or more ⁇ g/kg and the mean systolic and diastolic blood pressure was monitored continuously throughout the procedure. Results are reported with comparison to bPTH-(l-34) .
  • the assay was performed according to Pang et al. , Blood Vessels, 22, 57 (1985) .
  • Sprague-Dawley rats were anaesthetized with pentobarbital and the tail artery excised and placed in ice-cold Krebs-Hanseleit solution (KHS) oxygenated with 95% 0 2 , 5% C0 2 -
  • KHS Krebs-Hanseleit solution
  • Each artery was cut helically and strips of approximately 1.5 cm were secured in a Sawyer-Bartlestone chamber containing KHS.
  • the force generated by the strips was measured with a Grass FT03 force displacement transducer and recorded on a polygraph. Isolated tail artery helical strips were equilibrated for 1 hour prior to use.
  • the solution was continously aerated by a gas mixture of 95% 0 2 -5% C0 2 .
  • the right atrium was isolated and suspended in a tissue chamber containing 20 mL of PSS at 37°C, pH 7.4. Atria were allowed to equilibrate for 1 hr under a resting tension of 1 g.
  • the atrial rate and force were determined from contractions recorded by a Grass FT.03 force-displacement transducer and a Grass model 79 polygraph.
  • Dose-response curves for the peptides were obtained by cumulative addition of the respective peptides. Drug dose is calculated on the basis of the final concentration in the bath solution.
  • Intracellular free calcium concentration was measured using the fluorescent dye FURA-2 according to the method of Grynkiewicz et al., J. Biol. Chem.. 260, 3440 (1985) and Pang et al., P. N. A. S. (USA) . 87, 623 (1990) .
  • UMR-106 rat osteosarcoma cells (ATCC CRL-1661) are incubated in 1-10 ⁇ M FURA-2 AM (Sigma Chemical Co., St. Louis), the acetomethoxy ester of FURA-2.
  • FUR ⁇ -2 Upon hydrolysis within the cell, FUR ⁇ -2 is released which selectively binds to free Ca 2+ . Binding to Ca 2+ shifts the fluorescent spectrum of FUR ⁇ -2.
  • Quantitation is obtained by exciting the dye at two different wavelengths, preferably 340 and 380 nm and measuring the fluorescent emission at 510 nm.
  • concentration of calcium is proportional to the ratio of the fluorescence emitted at 340 nm to that at 380 nm.
  • KCl is used in the medium to stimulate Ca 2" ' " uptake. After the intracellular [Ca 2 ] ⁇ had been measured, the cells were washed with the original medium and the analogues added and the intracellular [Ca 2+ ] ⁇ measured again. KCl was then added without washing to measure the effect of the analogue on KCl induced Ca 2+ uptake. After measurement, the cells were washed with the medium 3-4 times and KCl again added to determine the recovery of the cells after removal of the analogue. Resu_ts are shown by actual traces and histograms summarizing the results. As can be seen from Figs. 10 a-d, PTII inhibits Ca 2+ uptake as measured by the method. Figs.
  • MOLECULE TYPE protein
  • MOLECULE TYPE peptide
  • SEQUENCE DESCRIPTION SEQ ID NO:25:
  • MOLECULE TYPE peptide
  • SEQUENCE DESCRIPTION SEQ ID NO:30:
  • MOLECULE TYPE protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Analogues of bovine and human parathyroid hormone, wherein the twenty-third amino acid of the natural hormone, tryptophane, has been substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Lys, Met, Pro, Ser or Thr have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-third amino acid as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.

Description

PARATHYROID HORMONE ANALOGUES AND USE IN OSTEOPOROSIS TREATMENT
\
FIELD OF THE INVENTION
This invention relates to analogues of parathyroid hormone 5 which, by substitution at the twenty-third position of natural parathyroid hormone, have been found to affect calcium change in bone cells without producing the typical effects of parathyroid hormone on systolic a d diastolic blood pressure, the effects on smooth muscle relaxation, vascular smooth muscle 10 calcium change as well as positive chronotropic and inotropic effects on the heart.
BACKGROUND OF THE INVENTION
Parathyroid hormone (hereinafter, PTH) is produced by the parathyroid gland and is involved in the control of calcium
15 levels in blood. It is a hypercalcemic hormone, elevating blood calcium levels. PTH is a polypeptide and the amino acid seguences of bovine and human PTH are closely related. Only the residues at locations one, seven and sixteen differ between the two. Synthetic polypeptides containing the first thirty-
20 four residues of PTII may be prepared using the method disclosed by Erickson and Merrifield, The Proteins. Neurath et al. , Eds. , Academic Tress, New York, 197G, page 257, preferably as modified by the method of Hodges et al., Peptide Research, 1, 19 (1988).
25 When serum calcium is reduced to below a "normal" level, the, parathyroid gland releases PTH and resorption of bone calcium and increased absorption of calcium from the intestine, as well as renal reabsorption of calcium, occur.
The antagonist of PTH is calcitonin, which acts to reduce
30 the level of circulating calcium. PTH is known to stimulate osteoclasts and its activity requires the presence of derivatives of vitamin ϋ- , especially 1,25- dihydroxycholecalciferol.
Intracellular calcium, particularly in the cells of the vascular system, has been shown to affect changes in vascular tension, as can be measured by changes in blood pressure. U.S. Patent Application 603,745 describes one method which has been discovered to regulate calcium uptake in vascular cells.
Osteoporosis is a progressive disease which is particularly characteristic of post enopausal women, and results in the reduction of total bone mass. The sequelae frequently involve fractures of load-bearing bones and the physical degenerations characteristic of immobilizing injuries. Osteoporosis is associated with hyperthyroidiεm, hypαrparathyroidism, Cushings syndrome and the use of certain steroidal drugs. Remedies historically have involved increase in dietary calcium, estrogen therapy and increased doses of vitamin D.
PTH has been used to treat osteoporosis. However, while the use of PTH is effective in the treatment of osteoporosis by diminishing the loss of bone mass, PTII may exhibit othαr undesired pharmalogical effects, sucli as hypotension and smooth muscle relaxation (e.g. relaxation of gastrointestinal organs, utorus?, tracheal and vas deferens) πs well ar, posi ivo chronotropic and inotropic effects on the heart. The relaxation effects of PTH on smooth muscle as well as positive chronotropic and inotropic effects of PTH are described in Pang et al, Trends in Pharmacological Sciences. Vol. 7, No. 9, pp. 340-341 (September 198G) .
U.S. Patent No. 4,771,124 discloses the property of bovine and human PTH analogues wherein Trp is substituted by amino acids phenylalanine, leucine, norleucine, valine, tyrosine, beta-naphtylalanine and alpha-naphtylalanine as a PTH antagonist. While it was suggested that these analogues might be useful in the treatment of osteoporosis, it was based on the analogues antagonistic action to PTII. Furthermore, there was no data to indicate the effectiveness these analogues on bone or other tissue. In addition, analogues with substituted at Trp23 with leucine, phenylalanine or tyrosine would produce undesired secondary effects of smooth muscle relaxation, vascular smooth muscle calcium change as well as positive tø chronotropic and inotropic effects on the heart.
5 Because PTH is a peptide, topical administration would be
« the preferred method of administration. However, topical application of PTH or the aforementioned analogues which exhibit vasoactivity would likely produce an undesired local vascular reaction. This reaction could be potentially
.1.0 detrimental if, for example, nasa] administration is employed.
It is one object of this invention to ameliorate bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure. It is another object of
15 this invention to identify that portion of PTH which is responsible for calcium regulation and that portion which appears to be primarily related to control of blood pressure and smooth muscle action.
BRIEF SUMMARY OF THE INVENTION
20 Modification of either bovine or human PTH at the twenty- third amino acid position to substitute for tryptophane either alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, lysine, methionine, proline, serine or threonine produces 25 essentially no change in systolic and diastolic blood pressure, no change in smooth muscle tension and no change in the rate and force of contraction of the heart as compared to native PTH. It also has been observed that the PTH analogue '. containing only the first thirty-four amino acids, with 30 substitution at the twenty-third position, is equally effective φ, in increasing the "osteo effect" without changing blood pressure or causing smooth muscle relaxation or positive chronotropic and inotropic effects on the heart.
The analogues of the present invention should be effective 35 in ameliorating bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. la shows the structure of natural bovine PTH (SEQ ID
NO:l) .
Fig. lb shows the structure of natural human PTH (SEQ ID NO:2) .
Fig. 2a shows the structure of bPTH (1-34) with position 23 substituted with Xaa (SEQ ID NO:3).
Figs. 2b-2p show the structure of bPTH (1-34) with position 23 substituted with Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, Ile, Lys, Met, Pro, Ser or Thr, respectively (SEQ ID NO:4 - SEQ ID NO:18) . Fig. 3a shows the structure of hPTH (1-34) with position
23 substituted with Xaa (SEQ ID NO:19).
Figs. 3b-3p show the structure of hPTH (1-34) with position 23 substituted with Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, Ile, Lys, Met, Pro, Ser or Thr, respectively (SEQ ID NO:20 - SEQ ID NO:34).
Fig. 4 shows the structure of bPTH with position 23 substituted with Xaa (SEQ ID NO:35).
Fig. 5 shows the structure of hPTH with position 23 substituted with Xaa (SEQ ID NO:36). Fig. 6 shows the effect of bPTH-(l-34) and its analogues on diastolic blood pressure of anestlietized Sprague-Dawley rats. Csll4 had no effect.
Fig. 7 shows the effect of bPTH-(l-34) and its analogues on systolic blood pressure of anesthetized Sprague-Dawley rats. Csll4 had no effect.
Fig. 8 shows the vasorelaxing effect of bPTH-(l-34) and its analogues on rat tail artery helical strip in vitro. Csll4 had no effect.
Fig. 9 shows the depolarizing concentrations of KCl which increased calcium ion levels in cultured osteoblasts. Drug 788 is an anti-osteoporotic agent which inhibits the KCl effect. Figs. 10 a-d show the depolarizing concentrations of KCl which increased calcium levels in cultured osteoblasts. Addition of bPTH-(l-34) inhibits the KCl effect.
Figs. 11 a-c show the depolarizing concentrations of KCl increasing calcium ion levels in cultured osteoblasts. Csll4 inhibits the KCl effect.
Fig. 12 shows the relation between the relaxation curves of Sprague-Dawley rat tail artery helical strips, precontracted with AVP when treated with Csll4, Csll7 and Cs201. Fig. 13 shows the effects illustrated in. Fig. 12, using
Cs206, CS207, Cs501, Cs502 and Cs503.
Fig. 14 shows the relaxation curves produced by Csll7, CΞ201, CsSOl, Cs502 and Cs503 on rat tail artery helical strips precontracted with KCl. Fig. 15 shows the relationship between the tension of rat tail artery helical strips depolarized with 10~7 M NE, as a function of calcium concentration in the presence of Csll4.
Fig. 16 shows the effect of Csll4 on the intracellular calcium concentration in the presence of KCl in UMR cells in culture.
Fig. 17 shows a comparison of the effect of Cs205 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
Fig. 18 shows the dose-response relationship between Cs205 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 19 shows a comparison of the effect of Cs201 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats. Fig. 20 shows the dose-response relationship between Cs201 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 21 shows a comparison of the effect of Cs503 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
Fig. 22 shows the dose-response relationship between Cs503 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 23 shows a comparison of the effect of Cs502 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats. Fig. 24 shows the dose-response relationship between Cs502 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 25 shows a comparison of the effect of Cs501 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
Fig. 26 shows the dose-response relationship between Cs501 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 27 comparison of the effect of Cs207 and bPTH on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.
Fig. 28 shows the dose-response relationship between Cs207 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP. Fig. 29 shows the effect of Cs207 on intracellular calcium increase stimulated by KCl in cultured UMR osteoblast cells.
Fig. 30 shows the effect of Cs207 on intracellular calcium increase stimulated by KCl in cultured UMR cells.
Fig. 31 shows a comparison of the effect of Cs206 and bPTH on the mean arterial blood pressure of anesthetized Sprague- Dawley rats.
Fig. 32 shows the dose-response relationship between Cs206 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP. Fig. 33 shows the effect of Cs206 on intracellular calcium concentration stimulated by KCl in cultured UMR osteoblast cells.
Fig. 34 shows the effect of Cs206 on intracellular calcium concentration stimulated by KCl in cultured UMR cells. Fig. 35 shows a comparison of the effect of Csll4 and bPTH on the systolic blood pressure of anesthetized Sprague-Dawley rats. Fig. 36 shows a comparison of the effect of Csll4 and bPTH on the diastolic blood pressure of anesthetized Sprague-Dawley rats.
Fig. 37 shows the dose-response relationship between Csll4 and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 38 shows the effect of Csll4 on intracellular calcium concentration stimulated by KCl in cultured UMR osteoblast cells. Fig. 39 shows the effect of Csl.1.4 (Λ) on intracellular calcium concentration stimulated by KCl in cultured UMR cells at 15 mM KCl.
Fig. 40 shows the effect of Csll4 (B) on intracellular calcium concentration stimulated by KCl in cultured UMR cells at 30 mM KCl.
Fig. 41 shows the effect of Cs88 [bPTH-(l-34) ] on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.
Fig. 42 shows the dose-response relationship between Cs88 [bPTII-(l-34) ] and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.
Fig. 43 shows the effect of Cs88 on intracellular calcium concentration stimulated by KCl in cultured UMR osteoblast cells.
Fig. 44 shows the effect of Cs88 on intracellular calcium concentration stimulated by KCl in cultured UMR cells.
Fig. 45 shows the effect of Csll3 on the intracellular calcium concentration stimulated by KCl in the presence of KCl. in UMR cells in culture.
Fig. 46 shows the effect of Cs501 on the intracellular calcium concentration stimulated by KCl in the presence of KCl in UMR cells in culture.
Fig. 47 shows the effect of CslOOl on the intracellular calcium concentration stimulated by KCl in the presence of KCl in UMR cells in culture. Fig. 48 shows the effect of Csll4 on the contractility and contraction rate of right atriai tissue of Sprague-Dawley rats.
Fig. 49 shows the effect of Cs201 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 50 shows the effect of Cs205 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 51 shows the effect of Cs206 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 52 shows the effect of Cs207 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 53 shows the effect of Cs208 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 54 shows the effect of Cs209 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 55 shows the effect of Cs211 on the contractility and contrnction rate of right atrial. tissue of Sprague-Dawley rats. Fig. 56 shows the effect of Cs212 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 57 shows the effect of Cs213 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 58 shows the effect of Cs214 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 59 shows the effect of Cs215 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 60 shows the effect of Cs220 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 61 shows the effect of Cs501 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 62 shows the effect of Cs503 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley ratr,, Fig. 63 shows the effect of Cs2001 and CslOOl on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
Fig. 64 shows the effect of Cs219 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.
Fig. 65 shows the effect of Cs218 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. Fig. 66 shows the effect of Cs502 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats. DETAILED DESCRIPTION OF THE INVENTION
There are at least two known catagories of functions for PTH. PTH is involved in calcium balance in the blood stream and controls both the amount of calcium uptake from the gastrointestinal tract and the deposition and removal of calcium from bone. Calcium also has been found to be effective in the maintenance of blood pressure. Cox, J. Cardiovascular Pharmacology, Vol. 8 (1986), Supp. 8 S48. Control of calcium in the walls of blood vessels is a useful therapeutic regimen for controlling hypertension and calcium channel blockers, which prevent the introduction of calcium into cell walls, is a conventional therapy for hypertension. Needleman et al. in Goodman and Gil an's The Pharmacological Basis of Therapeutics. MacMillan, New York, (1985), page 816 ff. Administration of therapeutic doses of PTH has been found to be effective for the control of osteoporosis, particularly in individuals who have been subjected to thyroidecto ies/ parathyroidectomies. Therapeutic dosages of PTH will, in some individuals, result in unacceptable diminution of blood pressure and may result in relaxation of smooth muscles such as gastrointestinal, uterus, tracheal, vas deferens as well as exhibit positive chronotropic and inotropic effects on the heart. To avoid hypotensive effects, smooth muscle relaxation effects and positive chronotropic and inotropic effects on the heart, it was envisaged that the structure of PTH could be modified to decouple the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic function from the bond calcium and bone deposition function. It has now been discovered that a critical site exists at amino acid twenty- three, which is tryptophane (Trp) in both bovine and human PTII. Substitution at the Trp site with other amino acids diminishes the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects without denigrating from the osteo effect. Particularly effective in this regard, is the substitution of alanine (Ala) or other amino acids lor Trp.
The* procedure of Erickson and Merrifield, as modified by Hodges et al.. as described above, may be used to synthesize synthetic PTH or fragments thereof. The procedure enables substitution for the naturally occurring PTH at substantially every location and it is possible to prepare both bovine and human synthetic PTH at full length or in the sequence of the first thirty-four amino acids, which is .more facilely performed. Such substitution can also be accomplished by genetic engineering.
Substitution at position twenty-three invariably alters the observed hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects, whether the full length PTH or the 1-34 fragment is administered. Substitution of Ala for Trp at position twenty-three is particularly preferred because the change in blood pressure, smooth muscle relaxation and positive chronotropic and inotropic effects from this substitution are minimal and calcium uptake, as measured in osteoblasts, mimics the results from the administration of native PTH. The 1-34 PTH fragment with Ala23 or other amino acids is particularly preferred because the pharmacological properties are those which are desired and the difficulty of synthesis is minimized. Synthesis of the compounds used in the development of this invention was performed at Alberta Peptide Institute (API) and the cooperation of API is gratefully acknowledged. The structure of bovine parathyroid hormone (bPTH) and human parathyroid hormone (hPTH) are shown in Figs, la (SEQ ID NO:l) and lb (SEQ ID NO:2). Representative synthetic analogues are described in Table 1 and are further shown in Figs. 2-5 and SEQ ID N0:3-SEQ ID NO:36. The hypotensive effects of these analogues is shown in Figs. 6, 7, 17, 19, 21, 23, 25, 27, 31, 35, 36, and 41. All of the analogues produce either no or less diminution of blood pressure than does native PTH. The Ala23 analogue provides almost no change in blood pressure, either systolic or diastolic, over a range of 0-5 μg/kg. At the level of 5 μg/kg of PTH, the blood pressure in Sprague-Dawley rats is such that they are essentially moribund.
We have developed a method for modeling the hypotensive effects of natural and synthetic chemical compounds using helically cut tail arteries from Sprague-Dawley rats in a Sawyer-Bartlestone chamber, measuring the change in tension with a force displacement transducer. This method and the effect of bovine PTH-(1-34) in this system is described in Blood vessels, 22, 57 (1985) . It is demonstrated in this paper that bPTH-(l-34) produces dose-dependent relaxation of helical strips of rat tail artery which have been previously contracted using arginine-vasopressin (AVP). Figs. 8, 12, 15, 18, 20, 22, 24, 26, 20, 32, 37 and 42 illustrate the effect of the PTH analogues of this invention as measured using this in vitro technique. Alternatively, the strips may be precontracted using other pressor substances such as norepinephrine (NE) or KCl. We have also developed a method of modeling the chronotropic effects of natural and synthetic chemicals using the right atrium from Sprague-Dawley rats and measuring the change in the force and rate of atrium contraction. This method and the effects of bovine PTH (1-34) in this system are described in Tenner et al, The Canadian Journal of Physiology and Pharmacology, Volume 61, No. 10 (1983) pp. 1162-ir67. It is demonstrated in this paper that bPTH (1-34) produces significant dose-dependent chronotropic effects on rat cardiac pacemaker tissue. Figs. 48-66 illustrate the effect of the PTH analogues of this invention as measured using this in vitro technique.
Because osteoporosis is a progressive syndrome, a model is required and the use of cultured osteoblasts of the UMR-106 rat osteosarcoma cells, ATCC CRL 1661 have been used as the model. Intracellular calcium concentration change in these cells has been monitored using the FURA-2 method, wherein a fluorescent dye which is specific for calcium is used as a marker for calcium uptake into the cells. Cells are incubated with 1-10 μM of the acetomethoxy ester of FURA-2 for 30-60 minutes. Upon uptake, the ester is hydrolyzed to release free FURΛ-2, which selectively binds free Ca +. FURΛ-2 has a characteristic fluorescence spectrum, which wavelength is shifted when the dye binds to free Ca2+. According to the method, Ca2+ which is present in the cell can be quantified by exciting the dye at two different wavelengths, 340 and 380 nm. The emission fluorescence is measured at 510 nm. The calcium concentration is proportional to the ratio of the fluorescent emission when excited at 340 nm to the emission at 380 nm. It is conventional to report the concentration of calcium within the cell in terms of the fluorescence ratio, the 340/380 ratio. This technique is described in Grynkiewicz et al. , J. Biol. Chem. , 260, 3440 (1985) and Pang et al., P. N. A. S. (USA) , 87, 623 (1990) .
Figs. 9, 10 a-d, 11 a-c, 16, 29, 30, 33, 34, 38, 39, 40, 43, 44 and 45-47 illustrate the results of the above-described measurements when inhibitors such as an anti-osteoporotic agent (788) or bPTH-(l-34) or Csll4 were used in the presence of KCl. As can be readily seen from the figures, the PTH analogues, whether full length or 1-34, which contain anomalous amino acids at position twenty-three (most particularly those which contain Ala23) do not effect a hypotensive and smooth muscle relaxation response, including positive chronotropic effects, but do inhibit calcium uptake as stimulated by KCl in osteoblasts, which indicates that these compounds would have the same effect on bone cells as PTH and would be useful in the treatment of osteoporosis in mammals and, particularly, in man, without the aformentioned deleterious side effects in the elderly-
While not being bound by any theory, it is suggested that substitution of Trp23 by other amino acids in 1-84 PTH and in the 1-34 analogues removes the vasodepressor, smooth muscle relaxation and positive chronotropic and inotropic effects of either bPTH or hPTH. The effect on KCl induced in osteoblasts, however, is essentially unchanged for 1-84 or 1-34 PTH. In other words, the effect on bone cells is unchanged from PTH. The physiological significance of an inhibiting effect on the KCL induced calcium uptake in bone cells is not yet understood. One hypothesis is that the analogues interact fully with bone cell receptor activity. The fact that the same effect is seen for both PTH and the analogues disclosed herein suggests that the site of interaction with the osteoblast cell receptor is unchanged by the substitution.
The analogues of trie present invention can be used in the 5 treatment of osteoporosis and other bone related diseases and disorders involving bone cell calcium regulation.
The analogues of the present invention may be administered to a warm-blooded mammalian in need thereof, particularly a human, by parental, topical, rectal administration or by
1.0 inhalation. The analogues may be conventionally formulated in a parenteral dosage form compounding about 1 to about 300 mg per unit of dosage with a conventional vehicle, excipient, binder, preservative, stabilizer, color, agent or the like as called for by accepted pharmaceutical practice. 5 For parental administration, a 1 to 10 ml intravenous, intramuscular or subcutaneous injection would be given one to four times daily. The injection would contain an analogue of the present invention in an aqueous isotonic sterile solution or suspension optionally with a preservative such as phenol or 0 a solubilizing agent such as ethylenediaminetetraacetic acid (EDTΛ) . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. 5 Synthetic monoglycerides, diglycerides, fatty acids (such as oleic acid) find use as fixed oil in the preparation of in ectables.
For rectal administration, the analogues of the present invention can be prepared in the form of suppositories by 0 mixing with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols.
For topical use, the analogues of the present invention can be prepared in the form of ointments, jellies, solutions, suspensions or dermal adhesive patches. 5 In a powdered aerosol, analogues of the present invention may be administered by a spinhaler turbo-inhaler device obtained from Fisons Corporation of Bedford, Massachusetts, at a rate of about 0.1 to 50 mg per capsule, 1 to 8 capsules being administered daily for an average human. In a liquid aerosol, the compounds of the present invention are administered at the rate of about 100 to 1000 micrograms per "puff" or activated release of a standard volume of propellant. The liquid aerosol would be given at the rate of 1 to 8 "puffs" per day with variation in dosages due to the severity of the conditions being treated, the weight of the patient and the particle size distribution of the aerosol. A fluorinated hydrocarbon or isobutane find use as propellants for liquid aerosols.
Daily doses are in the range of about 0.01 to about 200 mg per kg of body weight, depending on the activity of the specific compound, the age, weight, sex and conditions of the subject to be treated, the type and severity of the disease, the frequency and route of administration. As would be well known, the amount of active ingredient that may be combined with the carried materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration. The following examples demonstrate the utility of applicants' invention. The examples are not limiting, but are illustrative only, and modifications which would be apparent to those skilled in the art are included within the scope of this disclosure.
Example 1
In Vivo Blood Pressure Measurement.
Sprague-Dawley (S-D) rats were anaesthetized with pentobarbital and a cannula was inserted into the carotid artery. The rats were kept sedated during the procedure and were injected with PTH peptides only when the blood pressure of the rats were stable. Peptides were injected through a cannula in the jugular vein, in amounts of 1, 3 and 5 or more μg/kg and the mean systolic and diastolic blood pressure was monitored continuously throughout the procedure. Results are reported with comparison to bPTH-(l-34) .
Example 2
In Vitro Rat Tail Artery Helical Strip Tension Assay
The assay was performed according to Pang et al. , Blood Vessels, 22, 57 (1985) . Sprague-Dawley rats were anaesthetized with pentobarbital and the tail artery excised and placed in ice-cold Krebs-Hanseleit solution (KHS) oxygenated with 95% 02, 5% C02- Each artery was cut helically and strips of approximately 1.5 cm were secured in a Sawyer-Bartlestone chamber containing KHS. The force generated by the strips was measured with a Grass FT03 force displacement transducer and recorded on a polygraph. Isolated tail artery helical strips were equilibrated for 1 hour prior to use.
One to two minutes prior to addition of a peptide, the strips were contracted by addition of either arginine vnsopressin (AVP) , potassium chloride (KCl) or norepinephrine (NE) to the bath. The peptide was then added to the bath and the degree of relaxation measured. Bovine serum albumin was used as a control. Results are reported as percent decrease in tension for each drug and dose used. Drug dose is calculated on the basis of the final concentration in the bath solution. Example 3
In Vitro atrial contractility and contraction rate measurement The assay was performed according to Tenner et al. , Canadian Journal of Physiology and Pharmacology, Vol. 61, No. 10 (1983) pp. 1162-1167. Sprague-Dawley rats weighing between 100 and 250 g were treated with heparin (500 IU, i.p 15 minutes prior to decapitation. Thoracotomies were performed and the heart rapidly excised and placed in a cold physiological salt solution (PSS) having the following composition (in millimolar) : NaCl, 120; KCl, 5.63; CaCl-,, 2.0; MgCl2, 2.1; NaHC03, 25.0; dextrose, 9.7. The solution was continously aerated by a gas mixture of 95% 02-5% C02. The right atrium was isolated and suspended in a tissue chamber containing 20 mL of PSS at 37°C, pH 7.4. Atria were allowed to equilibrate for 1 hr under a resting tension of 1 g.
The atrial rate and force were determined from contractions recorded by a Grass FT.03 force-displacement transducer and a Grass model 79 polygraph. The Basial atrial rate for control atria (as determined by counting the frequency of contractions) was 258 ± 7 bpm (n=29) . Basal developed force of the spontaneously beating right atria was 0.33 ± 0.06 g (n=10) . Dose-response curves for the peptides were obtained by cumulative addition of the respective peptides. Drug dose is calculated on the basis of the final concentration in the bath solution.
Example 4
Measurement of Intracellular Free Calcium Concentration In
Vitro
Intracellular free calcium concentration was measured using the fluorescent dye FURA-2 according to the method of Grynkiewicz et al., J. Biol. Chem.. 260, 3440 (1985) and Pang et al., P. N. A. S. (USA) . 87, 623 (1990) . UMR-106 rat osteosarcoma cells (ATCC CRL-1661) are incubated in 1-10 μM FURA-2 AM (Sigma Chemical Co., St. Louis), the acetomethoxy ester of FURA-2. Upon hydrolysis within the cell, FURΛ-2 is released which selectively binds to free Ca2+. Binding to Ca2+ shifts the fluorescent spectrum of FURΛ-2. Quantitation is obtained by exciting the dye at two different wavelengths, preferably 340 and 380 nm and measuring the fluorescent emission at 510 nm. The concentration of calcium is proportional to the ratio of the fluorescence emitted at 340 nm to that at 380 nm.
KCl is used in the medium to stimulate Ca2"'" uptake. After the intracellular [Ca2 ]^ had been measured, the cells were washed with the original medium and the analogues added and the intracellular [Ca2+]^ measured again. KCl was then added without washing to measure the effect of the analogue on KCl induced Ca2+ uptake. After measurement, the cells were washed with the medium 3-4 times and KCl again added to determine the recovery of the cells after removal of the analogue. Resu_ts are shown by actual traces and histograms summarizing the results. As can be seen from Figs. 10 a-d, PTII inhibits Ca2+ uptake as measured by the method. Figs. 11 a-c, 16, 29, 30, 33, 34, 38, 39, 40, 44 and 45-47 illustrate comparable results for the aa23 analogues. The comparability of the analogues and PTH itself is considered to indicate that the analogues would be as useful as PTH for the treatment of osteoporosis.
Table I
Figure imgf000020_0001
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: PANG, Peter K.T. JIE, Shan (ii) TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES AS
OSTEOPOROTIC CONTROL AGENTS
(iii) NUMBER OF SEQUENCES: 36
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Armstrong, Nikaido, Marmelstein, Kubovci Murray
(B) STREET: 1725 K Street, N.W. , Suite 1000
(C) CITY: Washington D.C.
(E) COUNTRY: United States of America
(F) ZIP: 20006 (V) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Murray, Robert B.
(B) REGISTRATION NUMBER: 22,890
(C) REFERENCE/DOCKET NUMBER: 901930
(ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (202) 659-2930 (B) TELEFAX: (202) 887-0357
(C) TELEX: 440142
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser 35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His 50 55 60 Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu lie 65 70 75
Ala Lys Pro Gin
(2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His J.cπi 1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30 Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser S
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His G 50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile L 65 70 75 8
Ala Lys Pro Gin (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Ala Leu Arg Lys Lys Leu Gin Asp Val 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Arg Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Asn Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Ala Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15 Ser Met Glu Arg Val Glu Asp Leu Arg Lys Lys Leu Gin Asp Val H
20 25 • 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Cys Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15
Ser Met Glu Arg Val Glu Gin Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Glu Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
( i) SEQUENCE DESCRIPTION: SEQ ID NO:11: Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15
Ser Met Glu Arg Val Glu Gly Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15 Ser Met Glu Arg Val Glu His Leu Arg Lys Lys Leu Gin Asp Val H
20 25 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Ile Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15
Ser Met Glu Arg Val Glu Lys Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Met Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
( i) SEQUENCE DESCRIPTION: SEQ ID NO:16: Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15
Ser Met Glu Arg Val Glu Pro Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu S 1 5 10 15 Ser Met Glu Arg Val Glu Ser Leu Arg Lys Lys Leu Gin Asp Val H
20 25 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Thr Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOFO OGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Ala Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Arg Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15 Ser Met Glu Arg Val Glu Asn Leu Arg Lys Lys Leu Gin Asp Val H
20 25 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Asp Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15
Ser Met Glu Arg Val Glu Cys Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Gin Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15
Ser Met Glu Arg Val Glu Glu Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
( i) SEQUENCE DESCRIPTION: SEQ ID NO:27:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu As 1 5 10 15 Ser Met Glu Arg Val Glu Gly Leu Arg Lys Lys Leu Gin Asp Val Hi
20 25 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu His Leu Arg Lys Lys Leu Gin Asp Val H
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15
Ser Met Glu Arg Val Glu Ile Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Lys Leu Arg Lys Lys Leu Gin Asp-Val 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
( i) SEQUENCE DESCRIPTION: SEQ ID NO:31: Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Met Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15 Ser Met Glu Arg Val Glu Pro Leu Arg Lys Lys Leu Gin Asp Val H
20 25 30
Asn Phe (2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15 Ser Met Glu Arg Val Glu Ser Leu Arg Lys Lys Leu Gin Asp Val
20 25 30
Asn Phe
(2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15
Ser Met Glu Arg Val Glu Thr Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn Phe
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Ala Val Ser Glu Ile Gin Phe Met His Asn Leu Gly Lys His Leu 1 5 10 15
Ser Met Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gin Asp Val 20 25 30
Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser 35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His 50 55 60 Lys Ser Leu GJy Glu Λ.la Asp lys Ala Asp Val Asp Val Leu lie 65 70 75
Ala Lys Pro Gin
(2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Ser Val Ser Glu Ile Gin Leu Met His Asn Leu Gly Lys His Leu A 1 5 10 15
Ser Met Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gin Asp Val H 20 25 30 Asn he Val Ala Leu Gly Ala Ser lie Ala Tyr Arg Asp Gly Ser S
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His G 50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile L 65 70 75 8
Ala Lys Pro Gin

Claims

1. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:3, wherein Xaa is Alanine (Ala) , Arginine (Arg) , Asparagine (Asn) , Aspartic acid (Asp) , Cysteine (Cys) , Glutamine (Gin) , Glutamic acid (Glu) , Glycine (Gly) , Histidine (His) , Isoleucine (He) , Lysine (Lys) , Methionine (Met) , Proline (Pro) , Serine (Ser) or Threonine (Thr) .
2. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:4.
3. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:5.
4. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:6.
5. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:7.
6. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:8.
7. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:9.
8. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:10.
9. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:11.
10. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:12.
11. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:13.
12. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:14.
13. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:15.
14. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:16.
15. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:17.
16. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:18.
17. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:19, wherein Xaa is Alanine (Ala), Arginine (Arg) , Asparagine (Asn) , Aspartic acid (Asp) , Cysteine (Cys) , Glutamine (Gin) , Glutamic acid (Glu) , Glycine (Gly) ,
Histidine (His) , Isoleucine (Ile) , Lysine (Lys) , Methionine (Met) , Proline (Pro) , Serine (Ser) or Threonine (Thr) .
18. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:20.
19. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:21.
20. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:22.
21. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:23.
22. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:24.
23. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:25.
24. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:26.
25. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:27.
26. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:28.
27. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:29.
28. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:30.
29. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:31.
30. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:32.
31. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:33.
32. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:34.
33. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:35, wherein Xaa is Alanine (Ala), Arginine (Arg), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys) , Glutamine (Gin) , Glutamic acid (Glu) , Glycine (Gly) , Histidine (His) , Isoleucine (Ile) , Lysine (Lys) , Methionine (Met) , Proline (Pro) , Serine (Ser) or Threonine (Thr) .
34. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:36, wherein Xaa is Alanine (Ala) , Arginine (Arg) , Asparagine (Asn) , Aspartic acid (Asp) , Cysteine (Cys) , Glutamine (Gin) , Glutamic acid (Glu) , Glycine (Gly) , Histidine (His) , Isoleucine (Ile) , Lysine (Lys) , Methionine (Met) , Proline (Pro) , Serine (Ser) or Threonine (Thr) .
35. A pharmaceutical composition comprising a PTH analogue according to any one of claims 1-34 and a pharmaceutically acceptable carrier.
36. A method of treatment of osteoporosis in a patient in need of such treatment without causing substantial induction of hypotension, smooth muscle relaxation and cardiac inotropic and chronotropic action, said method comprising administering an osteoporotic effective amount of a PTH analogue according to any one of claims 1-34.
PCT/US1992/008478 1991-10-10 1992-10-09 Parathyroid hormone analogues and use in osteoporosis treatment WO1993006846A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77309791A 1991-10-10 1991-10-10
US773,097 1991-10-10

Publications (1)

Publication Number Publication Date
WO1993006846A1 true WO1993006846A1 (en) 1993-04-15

Family

ID=25097197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/008478 WO1993006846A1 (en) 1991-10-10 1992-10-09 Parathyroid hormone analogues and use in osteoporosis treatment

Country Status (2)

Country Link
AU (1) AU2807892A (en)
WO (1) WO1993006846A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040775A1 (en) * 1995-06-07 1996-12-19 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia
EP0847278A1 (en) * 1995-07-13 1998-06-17 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US6025467A (en) * 1995-06-15 2000-02-15 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives and their use
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
EP1567178A1 (en) * 2002-11-01 2005-08-31 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
WO2008019062A3 (en) * 2006-08-04 2009-04-09 Gen Hospital Corp Polypeptide derivatives of parathyroid hormone (pth)
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9057727B2 (en) 2007-08-01 2015-06-16 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040775A1 (en) * 1995-06-07 1996-12-19 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia
JP2008024709A (en) * 1995-06-07 2008-02-07 Syntex Usa Inc Method for the treatment of corticosteroid induced osteopenia
US6025467A (en) * 1995-06-15 2000-02-15 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives and their use
USRE40850E1 (en) 1995-07-13 2009-07-14 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
EP0847278A4 (en) * 1995-07-13 1999-01-13 Biomeasure Inc Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US6921750B2 (en) 1995-07-13 2005-07-26 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
EP0847278A1 (en) * 1995-07-13 1998-06-17 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
CN100412091C (en) * 1995-07-13 2008-08-20 提议和科学执行公司 parathyroid hormone analogs
US7632811B2 (en) 1995-07-13 2009-12-15 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7384912B2 (en) 2002-01-10 2008-06-10 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
EP1567178A1 (en) * 2002-11-01 2005-08-31 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
EP1567178A4 (en) * 2002-11-01 2009-07-15 Amgen Inc Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
WO2008019062A3 (en) * 2006-08-04 2009-04-09 Gen Hospital Corp Polypeptide derivatives of parathyroid hormone (pth)
JP2009545320A (en) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション Polypeptide derivative of parathyroid hormone (PTH)
US9057727B2 (en) 2007-08-01 2015-06-16 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof

Also Published As

Publication number Publication date
AU2807892A (en) 1993-05-03

Similar Documents

Publication Publication Date Title
US5317010A (en) Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US7410948B2 (en) Analogs of parathyroid hormone
RU2198182C2 (en) Analogs of parathyroid gland hormone
USRE40850E1 (en) Analogs of parathyroid hormone
JP2795449B2 (en) Therapeutic peptides
US5955425A (en) Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) Parathyroid hormone analogues for the treatment of osteoporosis
WO1993006846A1 (en) Parathyroid hormone analogues and use in osteoporosis treatment
JP2002523424A (en) New anti-diabetic peptide
IL106060A (en) Neuropeptide y (npy) antagonists and pharmaceutical compositions containing them
JPH11152299A (en) Novel amylin agonist peptide and use thereof
US5106834A (en) Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
AU723728B2 (en) Parathyroid hormone analogues for the treatment of osteoporosis
WO1991007978A1 (en) Synthetic calcitonin peptides
US5410019A (en) Therapeutic peptides
AU737057B2 (en) Cyclic CRF antagonist peptides
JP2002511067A (en) Cyclic CRF agonist
PT95016B (en) PROCESS FOR THE PREPARATION OF THERAPEUTIC PEPTIDES
JP2002522355A (en) New mixed amylin active compounds
US5135912A (en) Natriuretic peptides from the pituitary prohormone proopiomelanocortin
AU2011348220A1 (en) Cyclic CRF antagonist peptides
CA1340988C (en) Therapeutic peptides
AU622123C (en) Therapeutic peptides
CA2599885A1 (en) Parathyroid hormone analogues for the treatment of osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/67-67/67,DRAWINGS,REPLACED BY NEW PAGES 1/73-73/73;DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: KZ

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载